Olav Dalgard

Bilde av Olav Dalgard
English version of this page
Brukernavn
Besøksadresse Sykehusveien 25 None 1474 NORDBYHAGEN
Postadresse Akershus universitetssykehus 1478 LØRENSKOG

Publikasjoner

  • Dalgard, Olav; Weiland, Ola; Noraberg, Geir; Karlsen, Lars Normann; Heggelund, Lars; Färkkilä, Martti; Balslev, Ulla; Belard, Erika; Øvrehus, Anne; Kjær, Mette Skalshøi; Krarup, Henrik; Røge, Birgit Thorup; Hallager, Sofie; Madsen, Lone G.; Laursen, Alex Lund; Lagging, Martin & Weis, Nina (2017). Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections - A Scandinavian real-life study. PLoS ONE.  ISSN 1932-6203.  12:e0179764(7), s 1- 8 . doi: 10.1371/journal.pone.0179764
  • Grebely, Jason; Dalgard, Olav; Cunningham, Evan B.; Hajarizadeh, Behzad; Foster, Graham R.; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Amin, Janaki; Marks, Philippa S.; Quiene, Sophie; Applegate, Tanya L.; Weltman, Martin; Shaw, David; Dunlop, Adrian; Hellard, Margaret; Bruneau, Julie; Midgard, Håvard; Bourgeois, Stefan; Staehelin, Cornelia & Dore, Gregory J. (2017). Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. International journal of drug policy.  ISSN 0955-3959.  47, s 177- 186 . doi: 10.1016/j.drugpo.2017.05.020
  • Lamoury, François M.J.; Soker, Angelica; Martinez, Danica; Hajarizadeh, Behzad; Cunningham, Evan B.; Cunningham, Philip; Bruggmann, Philip; Foster, Graham R.; Dalgard, Olav; Backmund, Markus; Conway, Brian; Robaeys, Geert; Swan, Tracy; Cloherty, Gavin; Marks, Pip; Grebely, Jason; Dore, Gregory J. & Applegate, Tanya L. (2017). Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. Journal of Clinical Virology.  ISSN 1386-6532.  92, s 32- 38 . doi: 10.1016/j.jcv.2017.05.007
  • Meijerink, Hinta; White, Richard; Løvlie, Astrid Louise; De Blasio, Birgitte Freiesleben; Dalgard, Olav; Amundsen, Ellen Johanna; Melum, Espen & Kløvstad, Hilde (2017). Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973–2030. BMC Infectious Diseases.  ISSN 1471-2334.  17(1) . doi: 10.1186/s12879-017-2631-2
  • Midgard, Håvard; Hajarizadeh, Behzad; Cunningham, Evan B.; Conway, Brian; Backmund, Markus; Bruggmann, Philip; Bruneau, Julie; Bourgeois, Stefan; Dunlop, Adrian; Foster, Graham R.; Hellard, Margaret; Robaeys, Geert; Thurnheer, Maria C; Weltman, Martin; Amin, Janaki; Marks, Philippa S; Quiene, Sophie; Dore, Gregory J.; Dalgard, Olav & Grebely, Jason (2017). Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International journal of drug policy.  ISSN 0955-3959.  47, s 230- 238 . doi: 10.1016/j.drugpo.2017.05.040
  • Dore, Gregory J.; Altice, Frederick; Litwin, Alain H; Dalgard, Olav; Gane, Edward J.; Shibolet, Oren; Luetkemeyer, Anne; Nahass, Ronald; Peng, Cheng-Yuan; Conway, Brian; Grebely, Jason; Howe, Anita YM; Gendrano, Isaias N; Chen, Erluo; Huang, Hsueh-Cheng; Dutko, Frank J; Nickle, David C.; Nguyen, Bach-Yen; Wahl, Janice; Barr, Eliav; Robertson, Michael N & Platt, Heather L (2016). Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy a randomized trial. Annals of Internal Medicine.  ISSN 0003-4819.  165(9), s 625- 634 . doi: 10.7326/M16-0816
  • Dore, Gregory J.; Conway, Brian; Luo, Yan; Janczewska, Ewa; Knysz, Brygida; Liu, Yan; Streinu-Cercel, Adrian; Caruntu, Florin Alexandru; Curescu, Manuela; Skoien, Richard; Ghesquiere, Wayne; Mazur, Wlodzimierz; Soza, Alejandro; Fuster, Francisco; Greenbloom, Susan; Motoc, Adriana; Arama, Victoria; Shaw, David; Tornai, Istvan; Sasadeusz, Joseph; Dalgard, Olav; Sullivan, Danielle; Liu, Xuan; Kapoor, Mudra; Campbell, Andrew & Podsadecki, Thomas (2016). Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. Journal of Hepatology.  ISSN 0168-8278.  64(1), s 19- 28 . doi: 10.1016/j.jhep.2015.08.015
  • Midgard, Håvard; Bjøro, Benedikte; Mæland, Arild; Zbigniew, Konopski; Kileng, Hege; Damås, Jan Kristian; Paulsen, Jørn; Heggelund, Lars; Sandvei, Per; Ringstad, Jetmund; Karlsen, Lars Normann; Stene-Johansen, Kathrine; Pettersson, John; Dorenberg, Dagny Haug & Dalgard, Olav (2016). Hepatitis C reinfection after sustained virological response. Journal of Hepatology.  ISSN 0168-8278.  64(5), s 1020- 1026 . doi: 10.1016/j.jhep.2016.01.001
  • Midgard, Håvard; Bramness, Jørgen Gustav; Skurtveit, Svetlana; Haukeland, John Willy & Dalgard, Olav (2016). Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study. PLoS ONE.  ISSN 1932-6203.  11(11) . doi: 10.1371/journal.pone.0166451 Fulltekst i vitenarkiv. Vis sammendrag
  • Midgard, Håvard; Weir, Amanda; Palmateer, Nora; Lo Ve 3rd, Vincent; Pineda, Juan A.; Macias, Juan & Dalgard, Olav (2016). HCV epidemiology in high-risk groups and the risk of reinfection.. Journal of Hepatology.  ISSN 0168-8278.  1 Suppl, s 33- 45 . doi: 10.1016/j.jhep.2016.07.012
  • Waldenström, Jesper; Westin, Johan; Nyström, Kristina; Christensen, Peer; Dalgard, Olav; Färkkilä, Martti; Lindahl, Karin; Nilsson, Staffan; Norkrans, Gunnar; Krarup, Henrik; Norrgren, Hans; Buhl, Mads Rauning; Stenmark, Stephan & Lagging, Martin (2016). Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection. PLoS ONE.  ISSN 1932-6203.  11(5) . doi: 10.1371/journal.pone.0155142
  • Dalgard, Olav; Martinot-Peignoux, Michelle; Verbaan, Hans; Bjøro, Kristian; Ring-Larsen, Helmer & Marcellin, Patrick (2015). The usefulness of defining rapid virological response by a very sensitive assay (TMA) during treatment of HCV genotype 2/3 infection. PLoS ONE.  ISSN 1932-6203.  10(8) . doi: 10.1371/journal.pone.0120866
  • Gane, Edward J.; Kershenobich, D; Seguin-Devaux, C; Kristian, P; Aho, I; Dalgard, Olav; Shestakova, I; Nymadawa, P; Blach, S; Acharya, S; Anand, AC; Andersson, MI; Arendt, V; Arkkila, P; Baatarkhuu, O; Barclay, K; Ben-Ari, Z; Bergin, C; Bessone, F; Blokhina, N; Brunton, CR; Choudhuri, G; Chulanov, V; Cisneros, L; Croes, EA; Dahgwahdorj, YA; Daruich, JR; Dashdorj, NR; Davaadorj, D; De Knegt, RJ; De Vree, M; Gadano, AC; Gower, E; Halota, W; Hatzakis, A; Henderson, C; Hoffmann, P; Hornell, J; Houlihan, D; Hrusovsky, S; Jarcuska, P; Kostrzewska, K; Leshno, M; Lurie, Y; Mahomed, A; Mamonova, N; Mendez-Sanchez, N; Mossong, J; Norris, S; Nurmukhametova, E; Oltman, M; Oyunbileg, J; Oyunsuren, Ts; Papatheodoridis, G; Pimenov, N; Prins, M; Puri, P; Radke, S; Rakhmanova, A; Razavi, H; Razavi-Shearer, K; Reesink, HW; Ridruejo, E; Safadi, R; Sagalova, O; Sanchez Avila, JF; Sanduijav, R; Saraswat, V; Schreter, I; Shah, SR; Shevaldin, A; Shibolet, O; Silva, MO; Sokolov, S; Sonderup, M; Souliotis, K; Spearman, CW; Staub, T; Stedman, C; Strebkova, EA; Struck, D; Sypsa, V; Tomasiewicz, K; Undram, L; Van Der Meer, AJ; Van Santen, D; Veldhuijzen, I; Villamil, FG; Willemse, S; Zuckerman, E; Zuure, FR; Prabdial-Sing, N; Flisiak, R & Estes, Chris R. (2015). Strategies to manage hepatitis C virus (HCV) infection disease burden - Volume 2. Journal of Viral Hepatitis.  ISSN 1352-0504.  22(1), s 46- 73 . doi: 10.1111/jvh.12352
  • Hatzakis, Angelos; Chulanov, V; Gadano, AC; Bergin, C; Ben-Ari, Z; Mossong, J; Schreter, I; Baatarkhuu, O; Acharya, S; Aho, I; Anand, AC; Andersson, MI; Arendt, V; Arkkila, P; Barclay, K; Bessone, F; Blach, S; Blokhina, N; Brunton, CR; Choudhuri, G; Cisneros, L; Croes, EA; Dahgwahdorj, YA; Dalgard, Olav; Daruich, JR; Dashdorj, NR; Davaadorj, D; De Knegt, RJ; De Vree, M; Estes, C; Flisiak, R; Gane, E; Gower, E; Halota, W; Henderson, C; Hoffmann, P; Hornell, J; Houlihan, D; Hrusovsky, S; Jarcuska, P; Kershenobich, D; Kostrzewska, K; Kristian, P; Leshno, M; Lurie, Y; Mahomed, A; Mamonova, N; Mendez-Sanchez, N; Norris, S; Nurmukhametova, E; Nymadawa, P; Oltman, M; Oyunbileg, J; Oyunsuren, T; Papatheodoridis, G; Pimenov, N; Prabdial-Sing, N; Prins, M; Radke, S; Rakhmanova, A; Razavi-Shearer, K; Reesink, HW; Ridruejo, E; Safadi, R; Sagalova, O; Sanchez Avila, JF; Sanduijav, R; Saraswat, V; Seguin-Devaux, C; Shah, SR; Shestakova, I; Shevaldin, A; Shibolet, O; Silva, MO; Sokolov, S; Sonderup, M; Souliotis, K; Spearman, CW; Staub, T; Stedman, C; Strebkova, EA; Struck, D; Sypsa, V; Tomasiewicz, K; Undram, L; Van Der Meer, AJ; Van Santen, D; Veldhuijzen, I; Villamil, FG; Willemse, S; Zuckerman, E; Zuure, FR; Puri, P & Razavi, Homie A. (2015). The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - Volume 2. Journal of Viral Hepatitis.  ISSN 1352-0504.  22(1), s 26- 45 . doi: 10.1111/jvh.12351
  • Isaksen, Kjetil; Aabakken, Lars; Grimstad, Tore; Karlsen, Lars Normann; Sandvei, Per & Dalgard, Olav (2015). Hepatitt C-behandling ved tre norske sykehus 2000–11. Tidsskrift for Den norske legeforening.  ISSN 0029-2001.  135(22), s 2052- 2058 . doi: 10.4045/tidsskr.14.1478
  • Saraswat, Vivek Anand; Norris, S; De Knegt, RJ; Sanchez Avila, JF; Sonderup, M; Zuckerman, E; Arkkila, P; Stedman, C; Acharya, S; Aho, I; Anand, AC; Andersson, MI; Arendt, V; Baatarkhuu, O; Barclay, K; Ben-Ari, Z; Bergin, C; Bessone, F; Blach, S; Blokhina, N; Brunton, CR; Choudhuri, G; Chulanov, V; Cisneros, L; Croes, EA; Dahgwahdorj, YA; Dalgard, Olav; Daruich, JR; Dashdorj, NR; Davaadorj, D; De Vree, M; Estes, C; Flisiak, R; Gadano, AC; Gane, E; Halota, W; Hatzakis, A; Henderson, C; Hoffmann, P; Hornell, J; Houlihan, D; Hrusovsky, S; Jarcuska, P; Kershenobich, D; Kostrzewska, K; Kristian, P; Leshno, M; Lurie, Y; Mahomed, A; Mamonova, N; Mendez-Sanchez, N; Mossong, J; Nurmukhametova, E; Nymadawa, P; Oltman, M; Oyunbileg, J; Oyunsuren, T; Papatheodoridis, G; Pimenov, N; Prabdial-Sing, N; Prins, M; Puri, P; Radke, S; Rakhmanova, A; Razavi, H; Razavi-Shearer, K; Reesink, HW; Ridruejo, E; Safadi, R; Sagalova, O; Sanduijav, R; Schreter, I; Seguin-Devaux, C; Shah, SR; Shestakova, I; Shevaldin, A; Shibolet, O; Sokolov, S; Souliotis, K; Spearman, CW; Staub, T; Strebkova, EA; Struck, D; Tomasiewicz, K; Undram, L; Van Der Meer, AJ; Van Santen, D; Veldhuijzen, I; Villamil, FG; Willemse, S; Zuure, FR; Silva, MO; Sypsa, V & Gower, Erin E. (2015). Historical epidemiology of hepatitis C virus (HCV) in select countries - Volume 2. Journal of Viral Hepatitis.  ISSN 1352-0504.  22(1), s 6- 25 . doi: 10.1111/jvh.12350
  • Kielland, Knut Boe; Amundsen, Ellen Johanna & Dalgard, Olav (2014). HCV treatment uptake in people who have injected drugs — observations in a large cohort that received addiction treatment 1970–1984. Scandinavian Journal of Gastroenterology.  ISSN 0036-5521.  49(12), s 1465- 1472 . doi: 10.3109/00365521.2014.968860 Vis sammendrag
  • Kielland, Knut Boe; Delaveris, Gerd Jorunn Møller; Rogde, Sidsel; Eide, Tor Jacob; Amundsen, Ellen Johanna & Dalgard, Olav (2014). Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study. Journal of Hepatology.  ISSN 0168-8278.  60(2), s 260- 266 . doi: 10.1016/j.jhep.2013.09.022 Fulltekst i vitenarkiv. Vis sammendrag
  • Grady, Bart P.; Schinkel, Janke; Thomas, Xiomara V. & Dalgard, Olav (2013). Hepatitis C Virus Reinfection Following Treatment Among People Who Use Drugs. Clinical Infectious Diseases.  ISSN 1058-4838.  57, s S105- S110 . doi: 10.1093/cid/cit301
  • Kielland, Knut Boe; Skaug, Kjell; Amundsen, Ellen Johanna & Dalgard, Olav (2013). All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. Journal of Hepatology.  ISSN 0168-8278.  58(1), s 31- 37 . doi: 10.1016/j.jhep.2012.08.024 Vis sammendrag
  • Lagging, Martin; Rembeck, Karolina; Buhl, Mads Rauning; Christensen, Peer Brehm; Dalgard, Olav; Färkkilä, Martti; Hellstrand, Kristoffer; Langeland, Nina; Lindh, Mats; Westin, Johan & Norkrans, Gunnar (2013). Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scandinavian Journal of Gastroenterology.  ISSN 0036-5521.  48(7), s 839- 847 . doi: 10.3109/00365521.2013.793389
  • Robaeys, Geert; Grebely, Jason; Mauss, Stefan; Bruggmann, Philip; Moussalli, Joseph; De Gottardi, Andrea; Swan, Tracy; Arain, Amber; Kautz, Achim; Stöver, Heino; Wedemeyer, Heiner; Schaefer, M; Taylor, L; Backmund, Markus; Dalgard, Olav; Prins, Maria & Dore, Gregory J. (2013). Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases.  ISSN 1058-4838.  57, s S129- S137 . doi: 10.1093/cid/cit302
  • Béziat, Vivien; Dalgard, Olav; Asselah, Tarik; Halfon, Philippe; Bedossa, Pierre; Boudifa, Ali; Hervier, Baptiste; Theodorou, Ioannis; Martinot, Michelle; Debre, Patrice; Björkström, Niklas K; Malmberg, Karl-Johan; Marcellin, Patrick & Vieillard, Vincent (2012). CMV drives clonal expansion of NKG2C(+) NK cells expressing self-specific KIRs in chronic hepatitis patients. European Journal of Immunology.  ISSN 0014-2980.  42(2), s 447- 457 . doi: 10.1002/eji.201141826
  • Eskesen, Arne N; Melum, Espen; Moghaddam, Amir; Bjøro, Kristian; Verbaan, Hans; Ring-Larsen, Helmer & Dalgard, Olav (2012). Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. European Journal of Gastroenterology and Hepathology.  ISSN 0954-691X.  24(8), s 890- 896 . doi: 10.1097/MEG.0b013e3283546efd
  • Moghaddam, Amir; Melum, Espen; Reinton, Nils; Ring-Larsen, Helmer; Verbaan, Hans; Bjøro, Kristian & Dalgard, Olav (2011). IL28B Genetic Variation and Treatment Response in Patients with Hepatitis C Virus Genotype 3 Infection. Hepatology.  ISSN 0270-9139.  53(3), s 746- 754 . doi: 10.1002/hep.24154
  • Sulkowski, Mark S.; Cooper, Curtis; Hunyady, Bela; Jia, Jidong; Ogurtsov, Pavel; Peck-Radosavljevic, Markus; Shiffman, Mitchell L.; Yurdaydin, Cihan & Dalgard, Olav (2011). Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nature reviews: Gastroenterology & hepatology.  ISSN 1759-5045.  8(4), s 212- 223 . doi: 10.1038/nrgastro.2011.21
  • Dalgard, Olav; Bjøro, Kristian; Ring-Larsen, H. & Verbaan, H (2010). In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials. European Journal of Gastroenterology and Hepathology.  ISSN 0954-691X.  22(5), s 552- 556 . doi: 10.1097/MEG.0b013e328335b29e
  • Mangia, Alessandra; Dalgard, Olav; Minerva, Nicola; Verbaan, Hans; Bacca, David A.; Ring-Larsen, Helmer; Copetti, Massimiliano; Carretta, Vito; Piazzolla, Valeria; Cozzolongo, Raffaele; Mottola, Leonardo & Andriulli, Angelo (2010). Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Alimentary Pharmacology and Therapeutics.  ISSN 0269-2813.  31(12), s 1346- 1353 . doi: 10.1111/j.1365-2036.2010.04290.x
  • Midgard, Håvard; Bang, Christina; Raknerud, Nils & Dalgard, Olav (2010). Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin. Scandinavian Journal of Gastroenterology.  ISSN 0036-5521.  45(12), s 1503- 1508 . doi: 10.3109/00365521.2010.510571
  • Björnsson, Einar; Verbaan, Hans; Oksanen, Antti; Frydén, Aril; Johansson, Jonas; Friberg, Sarah; Dalgard, Olav & Kalaitzakis, Evangelos (2009). Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scandinavian Journal of Gastroenterology.  ISSN 0036-5521.  44(7), s 878- 887 . doi: 10.1080/00365520902898135
  • Dalgard, Olav; Bjoro, K; Ring-Larsen, H; Bjornsson, E; Holberg-Petersen, M; Skovlund, Eva; Reichard, O; Myrvang, B; Sundelof, B; Ritland, S; Hellum, K; Fryden, A; Florholmen, J & Verbaan, H (2008). Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology.  ISSN 0270-9139.  47, s 35- 42 . doi: 10.1002/hep.21975
  • Dalgard, Olav; Bjøro, T.; Hellum, K; Myrvang, Bjørn; Ritland, S; Skaug, Kjell; Raknerud, Nils & Bell, Helge (2004). Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology.  ISSN 0270-9139.  40(6), s 1260- 65
  • Dalgard, Olav; Egeland, Atle; Skaug, Kjell; Vilimas, Kostas & Steen, Tore (2004). Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology.  ISSN 0270-9139.  39(1), s 74- 80
  • Casey, P; Birbeck, G; McDonagh, C; Horgan, A; Dowrick, C; Dalgard, Olav; Lethinen, V; Ayuso-Mateos, JL; Dunn, G; Page, H; Wilkinson, C; Wilkinson, G & Vazquez-Barquero, JL (2004). Personality disorder, depression and functioning: results from the ODIN study. Journal of Affective Disorders.  ISSN 0165-0327.  82, s 277- 283
  • Dalgard, Olav; Jeansson, Stig Leo; Skaug, Kjell; Raknerud, Nils & Bell, Helge (2003). Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scandinavian Journal of Gastroenterology.  ISSN 0036-5521.  38(8), s 864- 70
  • Bell, Helge; Dalgard, Olav; Bjøro, Kristian; Hellum, Kjell B. & Myrvang, Bjørn (2002). Treatment of chronic hepatitis C. Tidsskrift for Den norske legeforening.  ISSN 0029-2001.  122, s 926- 28
  • Dalgard, Olav; Bjøro, Kristian; Hellum, Kjell B.; Myrvang, Bjørn; Bjøro, Trine; Haug, Egil & Bell, Helge (2002). Thyroid dysfunction during treatment if chronic hepatitis C with interferon alpha: no association with either interferon dosage of efficacy of therapy. Journal of Internal Medicine.  ISSN 0954-6820.  252, s 400- 406
  • Dalgard, Olav; Bjøro, Kristian; Hellum, Kjell B.; Myrvang, Bjørn; Skaug, Kjell; Gutigard, Bjørg-Guri & Bell, Helge (2002). Treatment of chronic hepatitis C in injecting drug users: 5 years follow-up. European Addiction Research.  ISSN 1022-6877.  8, s 45- 49

Se alle arbeider i Cristin

  • Razavi-Shearer, D; Dalgard, Olav; Midgard, Håvard; Razavi, H; Wüsthoff, Linda Elise & Kielland, Knut Boe (2016). Aggressive treatment of hepatitis C in People who inject drugs in Norway: an integral step to eradicate the infection in this population.
  • Hjerrild, Simon; Dalgard, Olav; Christensen, Peer Brehm & Leutscher, Peter (2015). Debilitating fatigue as a treatment indication in chronic hepatitis C. Journal of Hepatology.  ISSN 0168-8278.  63(6), s 1533- 1533 . doi: 10.1016/j.jhep.2015.08.003
  • Kielland, Knut Boe; Amundsen, Ellen Johanna & Dalgard, Olav (2013). Treatment uptake of HCV-infection in a Norwegian cohort of people who inject drugs..
  • Kielland, Knut Boe; Delaveris, Gerd Jorunn Møller; Rogde, Sidsel; Amundsen, Ellen Johanna; Eide, Tor Jacob & Dalgard, Olav (2013). Liver fibrosis among people who inject drugs exposed to hepatitis C, assessed through examination of liver tissue from autopsies.
  • Holter, Jan C.; Dalgard, Olav; Haukeland, John Willy; Hansen, Mona; Yndestad, Arne; Zbigniew, Konopski; Lannerstedt, Hans Christer; Kristoffersen, Anja Bråthen & Jonassen, Christine M (2012). Successful gene expression profiling in formalin-fixed and paraffin-embedded liver tissue from patients with chronic hepatitis C. Hepatology.  ISSN 0270-9139.  56(4), s 802A
  • Holter, Jan Cato; Dalgard, Olav; Haukeland, John Willy; Hansen, Mona Lindsethmo; Yndestad, Arne; Zbigniew, Konopski; Lannerstedt, Hans Christer; Kristoffersen, Anja Bråthen & Jonassen, Christine M (2012). Successful gene expression profiling in formalin-fixed and paraffin-embedded liver tissue from patients with chronic hepatitis C. Hepatology.  ISSN 0270-9139.  56, s 802A- 802A
  • Kielland, Knut Boe & Dalgard, Olav (2012). Mortality related to hepatitis B in injecting drug users. Hepatology.  ISSN 0270-9139.  56(Supp. 1), s 365A- 366A
  • Rembeck, Karolina; Norkrans, Gunnar P.; Dalgard, Olav; Langeland, Nina; Christensen, Peer B.; Buhl, Mads Rauning; Färkkilä, Martti A.; Hellstrand, Kristoffer & Lagging, Martin (2011). The efficiency of re-treatment with peg-interferon and ribavirin in patients with chronic hepatitis C infection genotype 2 or 3 with prior relapse. Hepatology.  ISSN 0270-9139.  54, s 1002A- 1003A
  • Dalgard, Olav; Moghaddam, Amir; Verbaan, Hans; Ring-Larsen, Helmer; Bjøro, Kristian & Melum, Espen (2010). IL28B GENETIC VARIATION AND TREATMENT RESPONSE IN PATIENTS WITH HCV GENOTYPE 3 INFECTION. Hepatology.  ISSN 0270-9139.  52(4), s 751A- 751A
  • Dalgard, Olav; Verbaan, H; Ring-Larsen, H & Bjøro, Kristian (2008). IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION AND RVR 14 WEEKS TREATMENT IS NON-INFERIOR TO 24 WEEKS. POOLED ANALYSIS OF TWO SCANDINAVIAN TRIALS. Hepatology.  ISSN 0270-9139.  48(4), s 1148A- 1148A
  • Kielland, Knut Boe; Dalgard, Olav & Skaug, Kjell (2008). Mortality and end-stage liver disease related to hepatitis C in injecting drug users.
  • Dalgard, Olav (2004). Hepatitis C virus infection in Oslo: Prevalence, clinical spectrum and treatment issues.
  • Dalgard, Olav; Bjøro, Kristian; Hellum, Kjell B.; Myrvang, Bjørn; Bjøro, Trine; Haug, Egil; Skaug, Kjell & Bell, Helge (2000). Thyroid dysfunction during treatment of chronic hepatitis C is associated with virological treatment response.
  • Dalgard, Olav; Bjøro, Kristian; Myrvang, Bjørn; Hellum, Kjell B.; Skaug, Kjell; Gutigard, Bjørg-Guri & Bell, Helge (2000). Long term follow-up after treatment of chronic hepatitis C with interferon-A. Reinfection in injecting drug users.
  • Dalgard, Olav; Hellum, Kjell B.; Bjøro, Kristian; Langtind, J.; Ritland, Ståle; Sundøy, A.; Haug, Egil & Bell, Helge (1999). Thyreoideasykdom ved behandling av kronisk hepatitt C med Interferon alfa.
  • Dalgard, Olav; Hellum, Kjell B.; Bjøro, Kristian; Myrvang, Bjørn; Bjøro, Trine; Haug, Egil & Bell, Helge (1999). Thyreoideasykdom ved behandling av kronisk hepatitt C med Interferon Alfa.

Se alle arbeider i Cristin

Publisert 6. juni 2014 14:24 - Sist endret 26. mai 2015 10:24